Cargando…

In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia

BACKGROUND: Podocyturia may determine the evolution to podocytopenia, glomerulosclerosis, and renal failure. According to the Oxford classification of IgA nephropathy (IgAN), the S1 lesion describes glomerulosclerosis. Urokinase-type plasminogen activator receptor (uPAR) participates in podocyte att...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trimarchi, Hernán, Canzonieri, Romina, Schiel, Amalia, Costales-Collaguazo, Cristian, Stern, Aníbal, Paulero, Matías, Rengel, Tatiana, Andrews, José, Iotti, Alejandro, Forrester, Mariano, Lombi, Fernando, Pomeranz, Vanesa, Iriarte, Romina, Muryan, Alexis, Zotta, Elsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473063/ https://www.ncbi.nlm.nih.gov/pubmed/28626472 http://dx.doi.org/10.1159/000473888

Ejemplares similares

In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride?
por: Trimarchi, H., et al.
Publicado: (2017)

Increased urinary CD80 excretion and podocyturia in Fabry disease
por: Trimarchi, H., et al.
Publicado: (2016)

Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
por: Trimarchi, H., et al.
Publicado: (2016)

Early decrease in the podocalyxin to synaptopodin ratio in urinary Fabry podocytes
por: Trimarchi, Hernán, et al.
Publicado: (2018)

Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
por: Trimarchi, Hernán, et al.
Publicado: (2017)

Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease
por: Trimarchi, H., et al.
Publicado: (2015)

Mucin-1 Gene Mutation and the Kidney: The Link between Autosomal Dominant Tubulointerstitial Kidney Disease and Focal and Segmental Glomerulosclerosis
por: Trimarchi, H., et al.
Publicado: (2018)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Proteinuria: an ignored marker of inflammation and cardiovascular disease in chronic hemodialysis
por: Trimarchi, Hernán, et al.
Publicado: (2011)

Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis
por: Trimarchi, H., et al.
Publicado: (2013)

Is There a Role for Mammalian Target of Rapamycin Inhibition in Renal Failure due to Mesangioproliferative Nephrotic Syndrome?
por: Trimarchi, Hernán, et al.
Publicado: (2012)

Podocyturia: What is in a name?
por: Trimarchi, Hernán
Publicado: (2015)

Podocyturia: Potential applications and current limitations
por: Trimarchi, Hernán
Publicado: (2017)

Proteinuria and its relation to diverse biomarkers and body mass index in chronic hemodialysis
por: Trimarchi, Hernán, et al.
Publicado: (2013)

Proteinuria, (99m)Tc-DTPA Scintigraphy, Creatinine-, Cystatin- and Combined-Based Equations in the Assessment of Chronic Kidney Disease
por: Trimarchi, Hernán, et al.
Publicado: (2014)

Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
por: Chen, Jin-Shuen, et al.
Publicado: (2016)

Podocyturia: Is there any clinical utility?
por: Yadav, I., et al.
Publicado: (2011)

Erratum to: Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models
por: Chen, Jin-Shuen, et al.
Publicado: (2017)

Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Shuai, Tiankui, et al.
Publicado: (2019)

Podocyturia: an earlier biomarker of cardiovascular outcomes
por: Eid, Assaad A., et al.
Publicado: (2022)

Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR
por: Trimarchi, H., et al.
Publicado: (2014)

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
por: Winnicki, Wolfgang, et al.
Publicado: (2019)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin
por: Hladunewich, Michelle A., et al.
Publicado: (2021)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study
por: Bacchiocchi, Roberta, et al.
Publicado: (2008)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Podocyturia: why it may have added value in rare diseases
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Parenteral Succinate Reduces Systemic ROS Production in Septic Rats, but It Does Not Reduce Creatinine Levels
por: Chapela, Sebastián P., et al.
Publicado: (2018)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts
por: Chao, Shih-Chun, et al.
Publicado: (2011)

Urokinase-type plasminogen activator receptor in IgA nephropathy
por: Ahn, Shin-Young, et al.
Publicado: (2014)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Urokinase-type Plasminogen Activator Induces Neurorepair in the Ischemic Brain
por: Merino, Paola, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dr1uqcvpd9qm21ih97skdrl24i